Objective
Give Life Science senior executives and their advisors and investors a broader view of the business and legal risks that exist in captive and contract manufacturing operations.
Who Should Attend
C-level executives; compliance officers; manufacturing, quality and IT leadership.
Why It’s Important
Risk is on the rise in the Life Science sector.
- Manufacturing processes are more complex, particularly for biopharma and drug-device combination products
- Growth in contract manufacturing creates challenges, including data visibility, IP ownership, post-patent competition and more
- Regulatory pressures are increasing from both the FDA and SEC
What You’ll Learn
Expect to leave the symposium with new insights on:
- Emerging risks in Life Science manufacturing
- Common weaknesses in Quality and Supply agreements
- Compliance challenges associated with FDA guidelines for process understanding
- SEC regulations for life sciences companies
CLICK HERE TO RESERVE YOUR SPACE NOW
newperspectivesonrisk.eventbrite.com
